(Q36359571)

13 August 2017

1 reference

title

T cell targeted immunotherapy for autoimmune disease (English)

1 reference

13 August 2017

1 reference

1 reference

Erica Lee

1

1 reference

PubMed ID

16390811

13 August 2017

Animesh A Sinha

series ordinal

2

1 reference

13 August 2017

1 December 2005

1 reference

13 August 2017

1 reference

13 August 2017

38

1 reference

13 August 2017

8

1 reference

13 August 2017

577-596

1 reference

Release of tumor necrosis factor, interleukin-2, and gamma-interferon in serum after injection of OKT3 monoclonal antibody in kidney transplant recipients

13 August 2017

1 reference

https://api.crossref.org/works/10.1080%2F08916930500418136

HuM291, a humanized anti-CD3 antibody, is immunosuppressive to T cells while exhibiting reduced mitogenicity in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08916930500418136

A humanized anti-CD3 antibody, HuM291, with low mitogenic activity, mediates complete and reversible T-cell depletion in chimpanzees

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08916930500418136

Phase I trial of HuM291, a humanized anti-CD3 antibody, in patients receiving renal allografts from living donors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08916930500418136

Modification of the Fc region of a primatized IgG antibody to human CD4 retains its ability to modulate CD4 receptors but does not deplete CD4(+) T cells in chimpanzees

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08916930500418136

Elimination of Fc receptor-dependent effector functions of a modified IgG4 monoclonal antibody to human CD4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08916930500418136

Differential effects of anti-B7-1 and anti-B7-2 monoclonal antibody treatment on the development of diabetes in the nonobese diabetic mouse

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08916930500418136

Evaluation of safety and clinical activity of multiple doses of the anti-CD80 monoclonal antibody, galiximab, in patients with moderate to severe plaque psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08916930500418136

A new member of the immunoglobulin superfamily--CTLA-4

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08916930500418136

CTLA-4 ligation blocks CD28-dependent T cell activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08916930500418136

CTLA-4 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08916930500418136

Functional expression of the costimulatory molecule, B7/BB1, on murine dendritic cell populations

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08916930500418136

Treatment of murine lupus with CTLA4Ig

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08916930500418136

CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08916930500418136

Blockade of T lymphocyte costimulation with cytotoxic T lymphocyte-associated antigen 4-immunoglobulin (CTLA4Ig) reverses the cellular pathology of psoriatic plaques, including the activation of keratinocytes, dendritic cells, and endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08916930500418136

Specific interaction of lymphocyte function-associated antigen 3 with CD2 can inhibit T cell responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08916930500418136

Alefacept, an immunomodulatory recombinant LFA-3/IgG1 fusion protein, induces CD16 signaling and CD2/CD16-dependent apoptosis of CD2(+) cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08916930500418136

An international, randomized, double-blind, placebo-controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08916930500418136

Selective targeting of T cell subsets: focus on alefacept - a remittive therapy for psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08916930500418136

Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08916930500418136

Treatment of psoriasis with alefacept: correlation of clinical improvement with reductions of memory T-cell counts.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08916930500418136

Investigational therapies for psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08916930500418136

Effects of administration of a single dose of a humanized monoclonal antibody to CD11a on the immunobiology and clinical activity of psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08916930500418136

Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08916930500418136

[Antegren (natalizumab). A promising new approach to therapy of multiple sclerosis]

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08916930500418136

Natalizumab for active Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08916930500418136

Antiadhesion molecule therapy in inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08916930500418136

Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08916930500418136

Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08916930500418136

Efficacy of a novel PEGylated humanized anti-TNF fragment (CDP870) in patients with rheumatoid arthritis: a phase II double-blinded, randomized, dose-escalating trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08916930500418136

Cytokine blocking agents in dermatology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08916930500418136

A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08916930500418136

Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08916930500418136

Interleukin-4 therapy of psoriasis induces Th2 responses and improves human autoimmune disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08916930500418136

Immune deviation strategies in the therapy of psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08916930500418136

Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNFalpha therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08916930500418136

A multicenter, double-blind, dose-ranging, randomized, placebo-controlled study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis: radiologic progression and correlation of Genant and Larsen scores

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08916930500418136

The multi-subunit interleukin-2 receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08916930500418136

Cytokines: interleukin and interferon therapy in dermatology

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08916930500418136

Interleukin-11 therapy selectively downregulates type I cytokine proinflammatory pathways in psoriasis lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08916930500418136

Dimethylfumarate for psoriasis: more than a dietary curiosity

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08916930500418136

Fumaric acid esters, their place in the treatment of psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08916930500418136

A novel anti-inflammatory role for simvastatin in inflammatory arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08916930500418136

Statins as potential therapeutic agents in neuroinflammatory disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08916930500418136

Estriol treatment ameliorates disease in males with experimental autoimmune encephalomyelitis: implications for multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08916930500418136

Estrogen receptor alpha mediates estrogen's immune protection in autoimmune disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08916930500418136

Review of in vivo pharmacokinetics and toxicology of phosphorothioate oligonucleotides.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08916930500418136

Double blind, placebo controlled trial of the remission inducing and steroid sparing properties of an ICAM-1 antisense oligodeoxynucleotide, alicaforsen (ISIS 2302), in active steroid dependent Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08916930500418136

Absence of efficacy of subcutaneous antisense ICAM-1 treatment of chronic active Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08916930500418136

Dose ranging pharmacokinetic trial of high-dose alicaforsen (intercellular adhesion molecule-1 antisense oligodeoxynucleotide) (ISIS 2302) in active Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08916930500418136

Antisense phosphorothioate oligodeoxynucleotides: introductory concepts and possible molecular mechanisms of toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08916930500418136

Therapeutic vaccination against adjuvant arthritis using autoimmune T cells treated with hydrostatic pressure

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08916930500418136

Control of experimental autoimmune uveoretinitis by low dose T cell vaccination.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08916930500418136

Vaccination against autoimmune mouse diabetes with a T-cell epitope of the human 65-kDa heat shock protein.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08916930500418136

T cell vaccination in secondary progressive multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08916930500418136

T cell vaccination in multiple sclerosis relapsing-remitting nonresponders patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08916930500418136

T cell vaccination in multiple sclerosis: results of a preliminary study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08916930500418136

Limited heterogeneity of T cell receptors from lymphocytes mediating autoimmune encephalomyelitis allows specific immune intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08916930500418136

Characterization of a major encephalitogenic T cell epitope in SJL/J mice with synthetic oligopeptides of myelin basic protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08916930500418136

Vaccination against experimental allergic encephalomyelitis with T cell receptor peptides

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08916930500418136

Immunization with a synthetic T-cell receptor V-region peptide protects against experimental autoimmune encephalomyelitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08916930500418136

Results of a phase I clinical trial of a T-cell receptor peptide vaccine in patients with multiple sclerosis. I. Analysis of T-cell receptor utilization in CSF cell populations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08916930500418136

TCR peptide therapy in human autoimmune diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08916930500418136

Predominant expression of T cell receptor V alpha 7 in tumor-infiltrating lymphocytes of uveal melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08916930500418136

T-cell receptor V alpha and C alpha alleles associated with multiple and myasthenia gravis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08916930500418136

Induction of a type 1 regulatory CD4 T cell response following V beta 8.2 DNA vaccination results in immune deviation and protection from experimental autoimmune encephalomyelitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08916930500418136

CDR1 T-cell receptor beta-chain peptide induces major histocompatibility complex class II-restricted T-T cell interactions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08916930500418136

Characterization of the antigen specificity and TCR repertoire, and TCR-based DNA vaccine therapy in myelin basic protein-induced autoimmune encephalomyelitis in DA rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08916930500418136

DNA immunization induces protective immunity against B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08916930500418136

Protection against mycoplasma infection using expression-library immunization

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08916930500418136

Preferential induction of a Th1 immune response and inhibition of specific IgE antibody formation by plasmid DNA immunization

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08916930500418136

DNA immunization to prevent autoimmune diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08916930500418136

Vaccination with glutamic acid decarboxylase plasmid DNA protects mice from spontaneous autoimmune diabetes and B7/CD28 costimulation circumvents that protection

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08916930500418136

Immunomodulatory vaccination in autoimmune disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08916930500418136

Tickling the TCR: selective T-cell functions stimulated by altered peptide ligands

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08916930500418136

Antigen-specific immunomodulation via altered peptide ligands

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08916930500418136

Peptide-based immunotherapy of autoimmunity: a path of puzzles, paradoxes and possibilities

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08916930500418136

Development of CD25(+) T cells secreting transforming growth factor-beta1 by altered peptide ligands expressed as self-antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08916930500418136

A dual altered peptide ligand down-regulates myasthenogenic T cell responses by up-regulating CD25- and CTLA-4-expressing CD4+T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08916930500418136

Specific antigen vaccination to treat autoimmune disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08916930500418136

Intranasal administration of insulin peptide B: 9-23 protects NOD mice from diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08916930500418136

Protection of nonobese diabetic mice from diabetes by intranasal or subcutaneous administration of insulin peptide B-(9-23)

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08916930500418136

Suppression of diabetes in nonobese diabetic mice by oral administration of porcine insulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08916930500418136

Insulin immunization of nonobese diabetic mice induces a protective insulitis characterized by diminished intraislet interferon-gamma transcription

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08916930500418136

Beta-cell function in new-onset type 1 diabetes and immunomodulation with a heat-shock protein peptide (DiaPep277): a randomised, double-blind, phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08916930500418136

Severe anaphylactic reactions to glutamic acid decarboxylase (GAD) self peptides in NOD mice that spontaneously develop autoimmune type 1 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08916930500418136

Prevention of diabetes by manipulation of anti-IGRP autoimmunity: high efficiency of a low-affinity peptide

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08916930500418136

Peptide analogs to pathogenic epitopes of the human acetylcholine receptor alpha subunit as potential modulators of myasthenia gravis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08916930500418136

Immunomodulation by a dual altered peptide ligand of autoreactive responses to the acetylcholine receptor of peripheral blood lymphocytes of patients with myasthenia gravis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08916930500418136

Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years. Copolymer 1 Multiple Sclerosis Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08916930500418136

Type I regulatory T cells specific for desmoglein 3 are more frequently detected in healthy individuals than in patients with pemphigus vulgaris

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08916930500418136

Loss of functional suppression by CD4+CD25+ regulatory T cells in patients with multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08916930500418136

Inhibition of T cell responses by activated human CD8+ T cells is mediated by interferon-gamma and is defective in chronic progressive multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08916930500418136

Therapeutic vaccination using CD4+CD25+ antigen-specific regulatory T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08916930500418136

In vitro-expanded antigen-specific regulatory T cells suppress autoimmune diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08916930500418136

Cancer regression in patients with metastatic melanoma after the transfer of autologous antitumor lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08916930500418136

Use of anti-CD3 monoclonal antibody to induce immune regulation in type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08916930500418136

Randomised, dose-ranging, placebo-controlled study of chimeric antibody to CD4 (keliximab) in chronic severe asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08916930500418136

Antibody-mediated stripping of CD4 from lymphocyte cell surface in patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08916930500418136

A population pharmacokinetic-pharmacodynamic analysis of single doses of clenoliximab in patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08916930500418136

HuMax-CD4: a fully human monoclonal anti-CD4 antibody for the treatment of psoriasis vulgaris.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08916930500418136

Depleting anti-CD4 monoclonal antibody cures new-onset diabetes, prevents recurrent autoimmune diabetes, and delays allograft rejection in nonobese diabetic mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08916930500418136

A randomized, double-blind, placebo-controlled trial of CDP571, a humanized monoclonal antibody to tumour necrosis factor-alpha, in patients with corticosteroid-dependent Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08916930500418136

Prevention and treatment of murine experimental allergic encephalomyelitis with T cell receptor V beta-specific antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08916930500418136

Depletion of Vbeta4 TCR does not induce resistance to EAN--further evidence for diversity of TCR usage.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08916930500418136

No effect of oral insulin on residual beta-cell function in recent-onset type I diabetes (the IMDIAB VII). IMDIAB Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08916930500418136

Effects of insulin in relatives of patients with type 1 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08916930500418136

Induction of a non-encephalitogenic type 2 T helper-cell autoimmune responsein multiple sclerosis after administration of an altered peptide ligand ina placebo-controlled, randomized phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08916930500418136

Vaccination against autoimmune encephalomyelitis with T-lymphocite line cells reactive against myelin basic protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08916930500418136

10.1080/08916930500418136

21 January 2018

Identifiers

DOI

1 reference

13 August 2017

1 reference

PubMed ID

16390811